HiFiBiO Therapeutics, an emerging multinational biotherapeutics company that seeks to combat diseases by mobilizing the human immune system, has raised $37.5 million in a Series B financing co-led by Sequoia China and LYFE Capital.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
